These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26174719)

  • 1. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).
    Bonora S; Rusconi S; Calcagno A; Bracchi M; Viganò O; Cusato J; Lanzafame M; Trentalange A; Marinaro L; Siccardi M; D'Avolio A; Galli M; Di Perri G
    J Antimicrob Chemother; 2015 Nov; 70(11):3096-9. PubMed ID: 26174719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.
    D'Avolio A; Carcieri C; Cusato J; Simiele M; Calcagno A; Allegra S; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2014 Nov; 69(11):3061-6. PubMed ID: 24997317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
    Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
    J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
    Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
    Saumoy M; Ordóñez-Llanos J; Martínez E; Ferrer E; Domingo P; Ribera E; Negredo E; Curto J; Sánchez-Quesada JL; Di Yacovo S; González-Cordón A; Podzamczer D
    J Antimicrob Chemother; 2015 Apr; 70(4):1130-8. PubMed ID: 25538166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial.
    Andersson LM; Vesterbacka J; Blaxhult A; Flamholc L; Nilsson S; Ormaasen V; Sönnerborg A; Gisslén M
    Scand J Infect Dis; 2013 Jul; 45(7):543-51. PubMed ID: 23294034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
    Cressey TR; Hazra R; Wiznia A; Foca M; Jean-Philippe P; Graham B; King JR; Britto P; Carey VJ; Acosta EP; Yogev R;
    Pediatr Infect Dis J; 2016 Dec; 35(12):1333-1335. PubMed ID: 27583590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study.
    Fatiguso G; Allegra S; Calcagno A; Baietto L; Motta I; Favata F; Cusato J; Bonora S; Perri GD; D'Avolio A
    Int J Pharm; 2016 Jan; 497(1-2):287-92. PubMed ID: 26642947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Ribera E; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Deulofeu R; Perez I; Gatell JM;
    Clin Infect Dis; 2015 Mar; 60(5):811-20. PubMed ID: 25389256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class-specific relative genetic contribution for key antiretroviral drugs.
    Siccardi M; Olagunju A; Simiele M; D'Avolio A; Calcagno A; Di Perri G; Bonora S; Owen A
    J Antimicrob Chemother; 2015 Nov; 70(11):3074-9. PubMed ID: 26221018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.